Clinical Trial

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Study acronym: CAR-T,MTD
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
Trial Details
NCT Number NCT07048353
Lead Sponsor Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Collaborators: Tongji Hospital Affiliated to Tongji Medical College of HUST, Shanxi Bethune Hospital, Wuhan Central Hospital, Yichang Central People's Hospital, First Affiliated Hospital of Guangxi Medical University
Conditions Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
Enrollment 15 participants
Start Date 2025-07-28
Primary Completion 2029-07-28 (estimated)
Study Completion 2029-07-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-02